PT-141 vs Turinabol
FDA Approved vs Moderate Research
monitor Mechanism-based · 51% Both PT-141 and Turinabol can raise blood pressure. Monitor BP regularly and consider adding cardiovascular support (cardarine, telmisartan, or similar).
Molecular Data
PT-141 Turinabol
Weight — 334.88 Da
Half-life ~2.7 hours ~16 hours
Type Melanocortin receptor agonist 17-alpha-alkylated anabolic-androgenic steroid (C20H27ClO2)
Key Benefits
PT-141
01 FDA-approved pharmaceutical route
02 Predictable absorption profile
03 Effective for both male and female sexual dysfunction
04 Works within 45 minutes
05 Effective in PDE5 inhibitor-resistant cases
06 Central mechanism (not dependent on blood flow)
Turinabol
01 Promotes lean, dry muscle gains without water retention or bloating
02 Does not aromatize to estrogen, eliminating risk of gynecomastia and estrogen-related side effects
03 Favorable anabolic-to-androgenic ratio, reducing androgenic side effects relative to muscle-building potential
04 Enhances muscular endurance and recovery through increased red blood cell production
05 Increases strength without significant body weight gain, beneficial for weight-class athletes
06 Improves creatine phosphate resynthesis, supporting repeated high-intensity efforts
07 Relatively mild androgenic profile compared to most oral anabolic steroids
08 Produces slow, steady, maintainable gains rather than rapid temporary increases
Dosing Protocols
PT-141
Women: 1.75mg (FDA-approved); Men: 1-2mg; Start 0.5mg test dose for tolerance / As needed before sexual activity; max 1 dose per 24 hours
Female HSDD (FDA-approved) 1.75mg As needed, max 1 dose/24hr
Male Erectile Dysfunction 1-2mg As needed, 45-60min before activity
Female Arousal Disorder 0.75-1.25mg As needed, max 1 dose/24hr
Low Starting Dose 0.5mg Test dose for tolerance assessment
Turinabol
30-60 mg/day (male) / Split into 2 doses daily (morning and evening)
Side Effects
PT-141
Nausea (40%)
Flushing (20%)
Headache (11%)
Injection site reactions
Turinabol
Hepatic stress with elevated liver enzymes (ALT, AST) -- moderate severity, dose- and duration-dependent
HDL cholesterol suppression (significant, often 30-50% reduction)
LDL cholesterol elevation
Suppression of endogenous testosterone production via HPG axis negative feedback
Mild gastrointestinal discomfort or nausea
Back pumps (lower back tightness during exercise, common with 17-alpha-alkylated compounds)
Oily skin and mild acne
Decreased appetite in some users
Contraindications
Uncontrolled hypertension
Cardiovascular disease
Use of nitrate medications
Pregnancy or breastfeeding
Known or suspected prostate cancer
Breast cancer in males
Pregnancy or planned pregnancy (teratogenic risk)
Active liver disease or significant hepatic impairment
Pre-existing severe dyslipidemia or cardiovascular disease
Hypersensitivity to turinabol or related compounds
Research Evidence
PT-141 Turinabol
Status FDA Approved Moderate Research
References 4 studies 5 studies
Latest 2022 June 2023
FDA Approved Yes No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.